Stocks Overview

LAST PRICE
33.9400
TODAY'S CHANGE (%)
Trending Up0.7900 (2.3831%)

Bid / Lots
33.0100/ 1
Ask / Lots
35.0000/ 1
Open / Previous Close
32.9700 / 33.1500
Day Range
Low 32.9700
High 34.9600
52 Week Range
Low 26.6100
High 66.3800
Volume
586,727
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 33.15
Time	Volume	GPCR
09:32 ET	3961	33
09:33 ET	200	33.19
09:35 ET	616	33.105
09:37 ET	2100	33.13
09:48 ET	12680	33.52
09:50 ET	13317	33.56
09:51 ET	1620	33.73
09:53 ET	7401	33.5572
09:55 ET	141	33.6
09:57 ET	3157	33.74
10:00 ET	2005	33.7
10:02 ET	314	33.76
10:04 ET	889	33.75
10:06 ET	2371	33.75
10:08 ET	2448	33.73
10:09 ET	400	33.7
10:11 ET	600	33.74
10:13 ET	200	33.74
10:15 ET	28108	33.99
10:18 ET	924	34.2
10:20 ET	700	34.2
10:22 ET	200	34.195
10:24 ET	654	34.52
10:26 ET	5700	34.76
10:27 ET	11891	34.64
10:29 ET	376	34.62
10:31 ET	2401	34.805
10:33 ET	688	34.76
10:36 ET	600	34.59
10:38 ET	100	34.57
10:40 ET	200	34.51
10:42 ET	300	34.46
10:44 ET	500	34.44
10:45 ET	9548	34.93
10:47 ET	982	34.92
10:49 ET	300	34.94
10:51 ET	1500	34.86
10:54 ET	1403	34.79
10:56 ET	1488	34.805
10:58 ET	750	34.6898
11:00 ET	460	34.73
11:03 ET	100	34.715
11:07 ET	1300	34.6
11:09 ET	1677	34.4599
11:12 ET	400	34.385
11:14 ET	300	34.395
11:16 ET	9316	34.49
11:18 ET	800	34.495
11:20 ET	708	34.43
11:21 ET	675	34.4
11:23 ET	300	34.47
11:25 ET	615	34.39
11:27 ET	200	34.385
11:30 ET	700	34.39
11:32 ET	1600	34.345
11:34 ET	100	34.355
11:36 ET	1172	34.43
11:38 ET	5503	34.41
11:39 ET	800	34.39
11:41 ET	1100	34.45
11:43 ET	200	34.465
11:48 ET	800	34.38
11:50 ET	1500	34.34
11:52 ET	1300	34.39
11:54 ET	200	34.47
11:56 ET	1300	34.44
11:57 ET	1326	34.4
11:59 ET	600	34.38
12:01 ET	200	34.365
12:03 ET	100	34.375
12:08 ET	500	34.47
12:10 ET	1700	34.47
12:12 ET	3385	34.605
12:14 ET	1200	34.63
12:15 ET	500	34.635
12:17 ET	7727	34.51
12:19 ET	410	34.41
12:21 ET	200	34.41
12:24 ET	1500	34.315
12:26 ET	300	34.28
12:28 ET	1900	34.44
12:30 ET	400	34.39
12:32 ET	350	34.41
12:33 ET	500	34.44
12:35 ET	2335	34.28
12:37 ET	10771	34.44
12:39 ET	5108	34.4925
12:42 ET	3345	34.5
12:44 ET	1210	34.4
12:46 ET	1800	34.485
12:48 ET	350	34.485
12:50 ET	2100	34.44
12:51 ET	3100	34.465
12:53 ET	460	34.42
12:55 ET	3539	34.56
12:57 ET	1722	34.56
01:00 ET	4687	34.455
01:04 ET	3936	34.29
01:06 ET	500	34.335
01:08 ET	300	34.33
01:09 ET	2804	34.49
01:11 ET	2805	34.41
01:13 ET	11284	34.38
01:15 ET	500	34.34
01:18 ET	1100	34.33
01:20 ET	500	34.39
01:22 ET	1743	34.44
01:24 ET	774	34.49
01:26 ET	4600	34.54
01:27 ET	700	34.48
01:29 ET	209	34.525
01:31 ET	2191	34.425
01:33 ET	809	34.405
01:36 ET	500	34.465
01:38 ET	600	34.43
01:40 ET	800	34.44
01:42 ET	400	34.45
01:44 ET	1578	34.5
01:45 ET	281	34.46
01:47 ET	100	34.49
01:49 ET	500	34.5
01:51 ET	1458	34.46
01:56 ET	14428	34.54
01:58 ET	1000	34.55
02:00 ET	1846	34.5675
02:03 ET	526	34.575
02:05 ET	4697	34.625
02:07 ET	300	34.645
02:09 ET	100	34.645
02:12 ET	1299	34.595
02:14 ET	300	34.565
02:16 ET	300	34.53
02:18 ET	1100	34.51
02:20 ET	1000	34.49
02:21 ET	2328	34.44
02:23 ET	850	34.355
02:25 ET	890	34.32
02:27 ET	1000	34.3
02:32 ET	200	34.28
02:34 ET	600	34.225
02:36 ET	100	34.255
02:38 ET	165	34.3078
02:39 ET	100	34.27
02:41 ET	800	34.155
02:43 ET	800	34.23
02:45 ET	1420	34.17
02:48 ET	382	34.11
02:50 ET	100	34.125
02:52 ET	100	34.15
02:56 ET	2150	34.15
02:57 ET	200	34.095
02:59 ET	400	34.06
03:01 ET	600	33.94
03:03 ET	544	33.99
03:06 ET	366	34.05
03:08 ET	325	33.995
03:10 ET	100	34.015
03:12 ET	200	34.02
03:14 ET	2254	34
03:15 ET	3762	34
03:17 ET	800	34.005
03:19 ET	500	33.96
03:21 ET	1400	33.9881
03:24 ET	884	33.99
03:26 ET	170	33.99
03:28 ET	2777	34.03
03:30 ET	1812	33.96
03:32 ET	1206	33.96
03:33 ET	1393	33.97
03:35 ET	968	33.98
03:37 ET	1562	33.965
03:39 ET	2000	33.995
03:42 ET	1800	34
03:44 ET	300	34
03:46 ET	630	34.035
03:48 ET	2716	34.01
03:50 ET	1205	34.12
03:51 ET	400	34.14
03:53 ET	4955	34.06
03:55 ET	1127	34.1534
03:57 ET	10104	33.79
04:00 ET	45567	33.94

Data delayed at least 15 minutes.

Nov 15, 2024
- Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  8:30AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
- Press Release: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
- Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
- Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesGPCR Structure Therapeutics Inc	1.9B	-15.4x	---
United StatesIRON Disc Medicine Inc	1.9B	-16.2x	---
United StatesNAMS NewAmsterdam Pharma Company NV	1.9B	-8.8x	---
United StatesCLDX Celldex Therapeutics Inc	1.9B	-10.6x	---
United StatesBLTE Belite Bio Inc	2.1B	-57.8x	---
United StatesTARS Tarsus Pharmaceuticals Inc	1.9B	-13.4x	---
As of 2024-12-03

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

Contact Information

Headquarters: 611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
Phone: ---
Fax: ---

Executives

Independent Chairman of the Board: Daniel Welch
Chief Executive Officer, Director: Raymond Stevens
Chief Financial Officer: Jun Yoon
Chief Technology Officer: Yingli Ma
Chief Scientific Officer: Xichen Lin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$1.9B
Revenue (TTM)	$0.00
Shares Outstanding	57.3M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	---
EPS	$-2.21
Book Value	$9.76
P/E Ratio	-15.4x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Structure Therapeutics Inc
NASDAQ:GPCRUnited States

Search Criteria

Charts

Recent News

Nov 15, 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 13, 2024

Press Release: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar